Patents
1) Authors: Fuentes Fayos, Antonio Carlos; Luque Huertas, Raúl Miguel; Jiménez Vacas, Juan Manuel; Solivera Vela, Juan; Blanco Acevedo, Cristóbal; Castaño Fuentes, Justo P.; Gahete Ortiz, Manuel D.; García García, Miguel Eduardo.
- Qualification: Compounds for the treatment of high grade astrocytoma. PCT/ES2022/070386
- Patent description: Patent relating to the use of splicing inhibitors for the treatment of brain tumours (high-grade astrocytomas).
- Owner Entity: University of Cordoba and Andalusia Health System.
2) Authors: Gahete Ortiz, Manuel David; Luque Huertas, Raúl Miguel; López Canovas, Juan Luis; Herman Sánchez, Natalia; Castaño Fuentes, Justo Pastor; Rodríguez Perálvarez, Manuel Luis Y Ciria Bru, Rubén.
- Qualification: EIF4A3 splicing factor as a biomarker in hepatocarcinoma. P202230647.
- Patent description: Patent relating to the use in vitro of EIF4A3 splicing factor expression levels as a biomarker of hepatocellular carcinoma and the development of in vitro methods for obtaining useful data and for the diagnosis and/or prognosis of hepatocellular carcinoma.
- Owner Entity: University of Cordoba and Andalusia Health System.
3) Authors: Luque Huertas, Raúl Miguel; Gahete Ortiz, Manuel David; Fuentes Fayos, Antonio Carlos; Castaño Fuentes, Justo Pastor; Ibáñez Costa, Alejandro; Vázquez Borrego, María Carmen; López López, Fernando; Blanco Acevedo, Cristóbal; Solivera Vela, Juan; Toledano Delgado, Álvaro; Gálvez Moreno, María Ángeles.
- Qualification: Method for the diagnosis and prognosis of the development of brain tumours in an individual. PCT/ES2021/070386 y P201931147.
- Patent description: Tool to diagnose and predict the progression of patients with different types of brain tumours, allowing to discriminate between healthy individuals and individuals with brain tumours with high sensitivity and specificity; to clinically stratify individuals based on clinical parameters and the expression of components of the splicing machinery in isolated tissue cells; and to facilitate the clinical follow-up of these individuals, contributing to the development of a personalised medicine.
- Owner Entity: University of Cordoba and Andalusia Health System
4) Authors: Lopez Canovas, Juan Luis; Gahete Ortiz, Manuel D; Luque Huertas, Raúl Miguel; Del Rio Moreno, Mercedes; Castano Fuentes, Justo; Rodriguez Peralvarez, Manuel; De La Mata, Manuel; Sanchez Frias, Marina Esther.
- Qualification: Compounds for the treatment of hepatocellular carcinoma. P202030723.
- Patent description: Compounds, compositions and combination preparations for the treatment of hepatocellular carcinoma, methods of diagnosis and for the selection of therapeutic agents useful in the prevention, amelioration, alleviation, and/or treatment of hepatocellular carcinoma.
- Owner Entity: University of Cordoba and Andalusia Health System
5) Authors: Luque Huertas, Raúl M.; Castaño Fuentes, Justo P.; Gahete Ortiz, Manuel D.; Hormaechea Agulla, Daniel; Requena Tapia, María José; Gómez Gómez, Enrique; Carrasco Valiente, Julia; Ibánez Costa, Alejandro; Moreno, María Del Mar Y Valero Rosa, José.
- Qualification: Ghrelin-O-acil transferase (GOAT) and its uses. PCT/ES2016/070844 y P201531731.
- Patent description: The present invention relates to the use of levels obtained ex vivo from a biological sample isolated from a subject of the amount or concentration of the enzyme ghrelin-O-acyl transferase (GOAT) or the mRNA encoding this protein, as an effective tool for obtaining data useful in the clinical diagnosis of prostate cancer.
- Owner Entity: University of Cordoba and Andalusia Health System
6) Authors: Luque Huertas, Raúl; Gahete Ortiz, Manuel David; Castaño Fuentes, Justo P.; Jiménez Vacas, Juan Manuel; Moráis Sarmento Borges, André; López López, Fernando; Requena Tapia, María José; Gómez Gómez, Enrique; Carrasco Valiente, Julia.
- Qualification: Method to diagnose or predict the development of prostate cancer in an individual. PCT/ES2020/070086 y P201930104.
- Patent description: Biomarkers, method, diagnostic kit and uses to diagnose, predict or predict the development of prostate cancer (PCa) in an individual.
- Owner Entity: University of Cordoba and Andalusia Health System
7) Authors (signature p.o.): Rosario Lopez Pedrera; Francisco Velasco Jimena; Carlos Perez Sanchez; Alejandro Ibañez Costa; Fernando Delgado Acosta; Juan Jose Ochoa Sepulveda; Rafael Oteros Fernandez.
- Qualification: Biomarkers of Stratification and prediction of the clinical evolution of stroke. P201930850
- Owner Entity: University of Cordoba and Andalusia Health System
- Patent description: The present invention proposes the evaluation of proteins from the thrombus of stroke patients as biomarkers for their stratification and prediction of evolution.
8) Authors (signature p.o.): Rosario López, Raul M. Luque, Carlos Pérez Sánchez, Eduardo Collantes, Rafaela Ortega, Justo P Castaño, Alejandro Ibáñez, Sergio Pedraza, Mercedes del Río Moreno, Nuria Barbarroja, Yolanda Jiménez.
- Qualification: Method of obtaining useful data for diagnosis; stratification and follow-up of patients with Rheumatoid arthritis. P201930123 and PCT/ES2019/070608
- Owner Entity: University of Cordoba and Andalusia Health System
- Patent description: The present invention proposes the standardized evaluation of a panel of biomarkers related to the splicing machinery, in leukocytes of patients with RA as a complement to their diagnosis, stratification, and/or monitoring.
Knowledge transfer projects
1) Title of the project: Spliceosomal approach to develop a personalized diagnostic and prognostic tool, with potential therapeutic impact in malignant brain tumors. Health Technology Development Project-ISCIII (DTS-23/00055).
- Responsible: Raúl Luque Huertas
- Contracting company: Instituto de Salud Carlos III
- Financing: 101.200 €.
- Start-end date: 2024-2026
2) Title of the project: Development of a tool for the diagnosis and prognosis of hormone- dependent cancers based on the analysis of soluble peptides derived from the somatostatin SST5TMD4 receptor (DTS22/00057).
- Responsible: Manuel David Gahete Ortiz
- Contracting company: Instituto de Salud Carlos III
- Financing: 84.700€.
- Start-end date: 2023-2025
3) Title of the project: Spliceosomal approach for the identification of diagnostic, prognostic and therapeutic biomarkers in paediatric brain tumours (FII22_01).
- Responsible: Raul Luque Huertas
- Contracting company: Instituto de Salud Carlos III
- Financing: 105.000 €.
- Start-end date: 2023-2025
4) Title of the project: Development of a diagnostic and prognostic tool, with potential therapeutic impact, in prostate cancer based on the analysis of components of the splicing machinery. Health Technology Development Project-ISCIII (DTS20/00050).
- Responsible: Raul Luque Huertas
- Contracting company: Instituto de Salud Carlos III
- Financing: 88.770 €.
- Start-end date: 2021-2023
5) Title of the project: Molecular and functional characterization of bladder cancer and castration-resistant prostate cancer: search for new therapies.
- Responsible: Raul Luque Huertas
- Contracting company: Eli Lilly & Company
- Financing: 74.800 €.
- Start-end date: 2022-2024
6) Title of the project: Evaluation of the effect of dopastatins on hormone secretion and cell viability in primary cultures of human cells derived from pituitary adenomas from patients with Cushings disease and non-functioning pituitary adenomas.
- Responsible: Raul Luque Huertas
- Contracting company: : IPSEN-SCRAS S.A.S.
- Financing: 52.352,94 €.
- Start-end date: 2019-2022.
7) Title of the project: Evaluation of the therapeutic relevance of sst3 in non-functioning pituitary adenomas (NFPA) using primary human NFPA cultures.
- Responsible: Raul Luque Huertas
- Contracting company: IPSEN-SCRAS S.A.S.
- Financing: 47.058 €.
- Start-end date: 2017-2019
8) Title of the project: GOAT (Ghrelin-O-acil transferase): new biomarker for prostate cancer screening (Ref: CI17-000015).
- Responsible: Raul Luque Huertas
- Contracting company: Social Work ¨La Caixa¨-Caixaimpulse.
- Financing: 70,000 €.
- Start-end date: 2017-2019